DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
DiaMedica Therapeutics Highlights DM199 Preeclampsia Data, Stroke Interim Catalyst at RedChip Conference
DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Average Rating of “Moderate Buy” by Brokerages
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
DiaMedica Therapeutics (DMAC) Expected to Announce Earnings on Monday
Brokerages Set DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Target Price at $12.33
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences
Leon Cooperman's Strategic Moves: Mr. Cooper Group Inc. Exits with -18.82% Impact
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of “Moderate Buy” by Brokerages
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA
DiaMedica Therapeutics Inc. (DMAC) Q3 2025 Earnings Call Transcript
DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
DiaMedica Therapeutics, Inc. (DMAC) is a Great Momentum Stock: Should You Buy?
After Golden Cross, DiaMedica Therapeutics, Inc. (DMAC)'s Technical Outlook is Bright
Wall Street Analysts Believe DiaMedica Therapeutics (DMAC) Could Rally 100.81%: Here's is How to Trade
What Makes DiaMedica Therapeutics, Inc. (DMAC) a Strong Momentum Stock: Buy Now?
Does DiaMedica Therapeutics (DMAC) Have the Potential to Rally 114.06% as Wall Street Analysts Expect?
DiaMedica: Interim Results Brings Study Expansions For DM199 In Preeclampsia
DiaMedica Therapeutics Inc. (DMAC) Q2 2025 Earnings Call Transcript
DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025
These 4 Stocks Are Seeing Huge Insider Buying
DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement
DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline
DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer
DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025
DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript
DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights
DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025
DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Call Transcript
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results
DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025
DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors